Britain and America have established a significant commercial pact that will preserve no import taxes on UK medicine exports being sold in the American market.
The Terms of the Deal
As part of the deal, the UK has committed to boost spending on pharmaceuticals through the public health system. This commitment ensures that duties on these crucial products will stay at nothing for a period of the next three years.
This agreement follows recent warnings to dramatically increase tariffs on branded drug imports, with potential rates floated up to double the cost.
"This agreement between the United Kingdom strengthens the global environment for new treatments and establishes long-overdue equity to transatlantic drug exports," a release noted.
Trade Impact
Drugs are one of the Britain's most significant export categories to the United States, which is clearly the largest market for large British pharmaceutical firms.
Export figures indicate that in the one-year period to the end of last September, the UK shipped drugs valued at billions to the US. This value made up nearly one-fifth of total UK exports in that period.
"This agreement safeguards employment, stimulates funding and sets the stage for the UK to emerge as a worldwide center for medical research," a government official commented.
Detailed NHS Changes
The deal entails several key commitments from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to double overall public funding on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must return to the NHS to prevent overspending will be limited at 15%. Last year, rebates were more than twenty percent.
Industry Background
This agreement follows a long-running row between the drug companies and the British authorities over drug pricing and regulatory access.
The disagreement were intensified by arguments that American patients were paying a premium for the same drugs than patients in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or scrapped, while substantial expansions have been pledged toward American operations.
The Science Minister acknowledged that the NHS must invest a greater share on drugs, noting that its spending on drugs had shrunk as a percentage of its resources over the last ten years.
